Selank: Research on the Tuftsin-Based Anxiolytic Peptide and Its GABAergic and Neurotrophin Mechanisms

Introduction: An Anxiolytic Peptide from Immunology Research

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences — the same research institution responsible for Semax. While Semax was developed from ACTH fragment research, Selank has a different origin: it is derived from tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced from immunoglobulin G and known for its immunomodulatory properties. Selank consists of tuftsin with a Gly-Glu-Asn tripeptide extension added to improve metabolic stability and CNS activity.

The research trajectory for Selank has focused primarily on anxiety, stress response, and cognitive function — a somewhat different emphasis than Semax’s neuroprotection-centered research. Both compounds are registered pharmaceuticals in Russia, though neither holds FDA approval or equivalent Western regulatory status.

This article reviews the published research on Selank, including its origin, proposed mechanisms, and documented findings from preclinical and clinical studies. All information is for educational and research purposes only.

From Tuftsin to Selank: Structural Background

Tuftsin (Thr-Lys-Pro-Arg) is a naturally occurring tetrapeptide cleaved from the Fc region of IgG by the enzyme tuftsinase. It was first characterized in the 1970s as an immune-stimulating peptide — promoting phagocytosis and macrophage activation. Subsequent research identified that tuftsin also has CNS activity, including effects on behavior and anxiety-related responses in animal models.

The modification from tuftsin to Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) involved adding a Pro-Gly-Pro extension at the C-terminus — the same stabilizing tripeptide used in Semax. This extension was incorporated to increase resistance to peptidase degradation and extend the compound’s active half-life in biological systems, enabling intranasal delivery with meaningful CNS bioavailability.

Proposed Mechanisms

GABAergic System Modulation

One of the primary proposed mechanisms for Selank’s anxiolytic effects involves modulation of the GABAergic system — the principal inhibitory neurotransmitter system in the brain and the target of classical anxiolytics including benzodiazepines. Published research indicates that Selank may enhance GABAergic transmission, and some studies have reported interactions with GABA-A receptor expression and subunit composition. Unlike benzodiazepines, which bind directly to GABA-A receptor allosteric sites, Selank’s GABAergic effects appear more indirect, potentially involving changes in receptor expression and modulatory protein interactions rather than direct receptor binding.

This mechanistic distinction — indirect GABAergic modulation rather than direct receptor binding — is proposed to explain why Selank may produce anxiolytic effects without the sedation, dependence risk, and tolerance development associated with benzodiazepines, though this comparison requires more rigorous human investigation to establish clinically.

BDNF and Neurotrophin Upregulation

Like Semax, Selank has been reported to upregulate BDNF expression in preclinical models. The neurotrophin-upregulating properties of Selank are less extensively characterized than its GABAergic and immunomodulatory mechanisms, but represent a shared feature with Semax that may contribute to overlapping cognitive effects reported for both compounds.

Enkephalin Metabolism

Published research has proposed that Selank inhibits enzymes responsible for degrading enkephalins — endogenous opioid pentapeptides involved in pain modulation, mood regulation, and stress responses. By extending enkephalin activity, Selank may influence opioid receptor signaling in ways that contribute to its reported anxiolytic and stress-modulating effects. This enkephalin-stabilizing mechanism has been proposed as a key component of Selank’s pharmacological profile.

Immunomodulatory Effects

Given its tuftsin-derived origin, Selank retains some immunomodulatory properties. Published data have reported effects on cytokine profiles and immune cell activity, including influences on interferon-gamma and interleukin expression. The immunological dimension of Selank’s biology is an area of ongoing research interest, particularly in the context of stress-immune axis interactions.

Preclinical Research Findings

Anxiety and Stress Models

The most extensive published preclinical research on Selank involves anxiety and stress models. In elevated plus maze, open field, and forced swim tests — standard preclinical anxiety and stress paradigms — Selank has demonstrated dose-dependent anxiolytic and antistress effects in rodents. The magnitude of anxiolytic effect in some published comparisons has been similar to reference anxiolytics, with a reportedly different side effect profile (notably, absence of sedation and motor impairment observed with benzodiazepines at anxiolytic doses).

Cognitive Performance

Published rodent research has also documented cognitive effects of Selank, including improvements in learning and memory task performance — effects that parallel the neurotrophic (BDNF) mechanism. This cognitive-enhancing dimension of Selank’s profile has positioned it as both an anxiolytic research candidate and a nootropic compound in the research literature.

Stress-Induced Immune Dysregulation

Some published preclinical research has examined Selank’s ability to modulate stress-induced changes in immune function, a research area that leverages both its anxiolytic and immunomodulatory properties. In stress models, Selank has been reported to attenuate stress-induced changes in immune cell parameters, consistent with the proposed stress-immune axis modulation.

Clinical Research and Registration in Russia

Selank is registered as a pharmaceutical in Russia for the treatment of anxiety disorders and as an adaptogen (a substance proposed to increase resistance to stress). Published Russian clinical data include trials in generalized anxiety disorder, asthenic conditions (fatigue and stress-related syndromes), and mixed anxiety-depressive states.

Published findings from Russian clinical trials have generally reported improvements in anxiety scores, cognitive function measures, and quality of life in treated populations compared to control or comparator groups. However, as with the Semax clinical literature, these data must be interpreted with appropriate context regarding study design standards and the difference between Russian regulatory registration and FDA or EMA approval processes.

Comparison with Semax

Semax and Selank are frequently discussed together given their shared Russian research origin, similar intranasal administration profile, and overlapping CNS activity. Key distinctions in their research profiles:

• Primary effect emphasis: Semax research is more heavily weighted toward neuroprotection, stroke, and cognitive enhancement; Selank research is more centered on anxiety, stress modulation, and adaptogenic effects
• Mechanism emphasis: Semax is more prominently associated with BDNF upregulation and monoamine effects; Selank is more prominently associated with GABAergic modulation and enkephalin stabilization
• Immunological dimension: Selank’s tuftsin-derived origin gives it a more developed immunomodulatory research profile than Semax

Both compounds share the Pro-Gly-Pro stabilizing extension, intranasal administration route, CNS bioavailability through olfactory pathways, and Russian clinical registration status.

Regulatory Status Outside Russia

Selank has no FDA approval, EMA approval, or equivalent Western regulatory status for any indication. It is available as a research compound and is referenced in nootropic and peptide research communities. Its use outside of formal research settings is not within approved medical channels.

Summary

Selank represents a distinct research pathway in neuropeptide science — an anxiolytic and adaptogenic peptide derived from immunology research, with proposed mechanisms spanning GABAergic modulation, enkephalin stabilization, BDNF upregulation, and immune regulation. Its preclinical data in anxiety models are consistent and well-documented. Its Russian clinical registration provides a higher level of human evidence than most research peptides, while falling short of the randomized controlled trial standards expected by FDA or EMA for new drug approval.

For researchers studying anxiety biology, peptide-based GABAergic modulation, stress-immune axis interactions, or comparative neuropeptide pharmacology, Selank offers a scientifically interesting profile with a documented research history that bridges immunology and CNS pharmacology.

All content on Peptide Research Blog is for educational and research purposes only. Selank is not FDA-approved. This content does not constitute medical advice.